文献速递炎症性肠病消化道肿瘤与早癌消化内镜

系统综述与Meta分析:炎症性肠病伴不确定型和低级别异型增生患者进展为进展期肿瘤的发生率及危险因素

Systematic review with meta-analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and low-grade dysplasia.
PubMed 文献 · Aliment Pharmacol Ther · 2022-02-15

该系统综述与Meta分析检索截至2021年12月24日的文献,纳入38项研究,评估炎症性肠病伴不确定型异型增生(IND)和低级别异型增生(LGD)患者进展期肿瘤的合并发生率及危险因素。IND和LGD患者进展期肿瘤的合并发生率分别为9.9%(95%CI 4.4%-15.4%)和10.7%(95%CI 7.0%-14.4%),两者相近。IND患者危险因素包括原发性硬化性胆管炎(PSC)和非整倍体;LGD患者危险因素包括男性、PSC、既往IND、结肠狭窄、指示病变≥1 cm、远端位置、多灶性病变、远端扁平病变、非息肉样/扁平病变和不可见病变。

要点

  • IBD伴IND患者进展期肿瘤合并发生率为9.9%(95%CI 4.4%-15.4%)。
  • IBD伴LGD患者进展期肿瘤合并发生率为10.7%(95%CI 7.0%-14.4%)。
  • IND与LGD进展期肿瘤发生率相近,约十分之一,建议对IND患者也进行更严密监测。

核心结论

  • IBD患者中IND与LGD进展为进展期肿瘤的发生率相似,高达十分之一,因此也建议对IND患者进行更严密的监测。
  • 由于多数因素的影响仅基于2至3项研究的合并结果,需要进一步研究证实。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase和Cochrane Central Register of Controlled Trials截至2021年12月24日,纳入报告IBD伴IND和LGD患者随访结肠镜或手术病理结果的研究,共分析38项研究。

主要发现

  • IBD伴IND患者进展期肿瘤的合并发生率为9.9%(95%CI 4.4%-15.4%)。
  • IBD伴LGD患者进展期肿瘤的合并发生率为10.7%(95%CI 7.0%-14.4%)。
  • IND患者进展期肿瘤的危险因素为原发性硬化性胆管炎(PSC)和非整倍体。
  • LGD患者进展期肿瘤的危险因素包括男性、PSC、既往IND、结肠狭窄、指示病变≥1 cm、远端位置、多灶性病变、远端和扁平病变、非息肉样/扁平病变和不可见病变。

临床怎么用

  • 作者建议对IND患者也进行更严密的监测。

局限性

  • 由于多数因素的影响仅基于2至3项研究的合并结果,需要进一步研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Due to limited research on the natural history of indefinite for dysplasia (IND) and low-grade dysplasia (LGD) in inflammatory bowel disease (IBD), the management of these patients is controversial. AIMS: This systematic review and meta-analysis aimed to estimate the incidence and identify the risk factors for advanced neoplasia in IBD patients with IND and LGD. METHODS: PubMed, Embase and Cochrane Central Register of Controlled Trials were searched until 24 December, 2021, to identify studies that reported pathological results of follow-up colonoscopy or surgery in IBD patients with IND and LGD. The main outcomes were the incidence and risk factors for advanced neoplasia in IBD patients with IND and LGD. RESULTS: Based on the analysis of 38 studies, the pooled incidences of advanced neoplasia in IBD patients with IND and LGD were 9.9% (95% CI 4.4%-15.4%) and 10.7% (95% CI 7.0%-14.4%) respectively. The risk factors for advanced neoplasia in IND patients were primary sclerosing cholangitis (PSC) and aneuploidy. The risk factors for advanced neoplasia in LGD patients included male, PSC, previous IND, colonic stricture, index lesion ≥1 cm, distal location, multifocal lesions, distal and flat lesions, nonpolypoid/flat lesions and invisible lesions. CONCLUSIONS: The incidence of advanced neoplasia was similar between IND and LGD in IBD patients, as high as one in ten, so more rigorous surveillance is also suggested in IND patients. Since the effects of most factors were derived from the pooled results of only two to three studies, further research was needed to confirm our results.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wan J, Wang X, Zhang Y, et al. Systematic review with meta-analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and low-grade dysplasia. Aliment Pharmacol Ther. 2022. PMID: 35166389. doi:10.1111/apt.16789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。